TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® [...] Read more »
Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis
- Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.
- Read more »
Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
- Kyowa Kirin réaffirme sa volonté de développer le rocatinlimab comme un traitement innovant capable d’améliorer significativement la vie des patients, tout en [...] Read more »
Kyowa Kirin Recupera Controle do Programa de Desenvolvimento e Comercialização do Rocatinlimab, Demonstrando Forte Compromisso para Abordar a Alta Necessidade Médica Não Atendida na Dermatite Atópica
- A Kyowa Kirin afirma o compromisso de desenvolver o rocatinlimab como um ativo diferenciado de mudança de vida com potencial de mercado significativo.
- Read more »
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
- Kyowa Kirin affirms commitment to developing rocatinlimab as a life–changing differentiated asset with significant market potential.
- Rocatinlimab’s novel approach as an investigational [...] Read more »
Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO
ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) — Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, today announced the appointment of Sergio Marullo di Condojanni as Chief [...] Read more »
Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset
- Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre–clinical investigational novel compound with broad potential to treat [...] Read more »
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.